Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Management of Malignant Pericardial Effusion.

Petrofsky M.

J Adv Pract Oncol. 2014 Jul-Aug;5(4):281-9. Review. No abstract available.

2.

Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice.

Bermudez LE, Inderlied CB, Kolonoski P, Chee CB, Aralar P, Petrofsky M, Parman T, Green CE, Lewin AH, Ellis WY, Young LS.

Antimicrob Agents Chemother. 2012 Aug;56(8):4202-6. doi: 10.1128/AAC.00320-12. Epub 2012 May 21.

3.

What is the Cause of This Patient's Symptoms?

Petrofsky M, Zitella L.

J Adv Pract Oncol. 2012 Mar;3(2):123-4. No abstract available.

4.
5.

Identification of virulence determinants of Mycobacterium avium that impact on the ability to resist host killing mechanisms.

Li YJ, Danelishvili L, Wagner D, Petrofsky M, Bermudez LE.

J Med Microbiol. 2010 Jan;59(Pt 1):8-16. doi: 10.1099/jmm.0.012864-0.

6.

The ability to form biofilm influences Mycobacterium avium invasion and translocation of bronchial epithelial cells.

Yamazaki Y, Danelishvili L, Wu M, Hidaka E, Katsuyama T, Stang B, Petrofsky M, Bildfell R, Bermudez LE.

Cell Microbiol. 2006 May;8(5):806-14.

PMID:
16611229
8.

A Mycobacterium avium PPE gene is associated with the ability of the bacterium to grow in macrophages and virulence in mice.

Li Y, Miltner E, Wu M, Petrofsky M, Bermudez LE.

Cell Microbiol. 2005 Apr;7(4):539-48.

PMID:
15760454
9.

SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.

Bermudez LE, Kolonoski P, Seitz LE, Petrofsky M, Reynolds R, Wu M, Young LS.

Antimicrob Agents Chemother. 2004 Sep;48(9):3556-8.

11.

Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.

Bermudez LE, Kolonoski P, Petrofsky M, Wu M, Inderlied CB, Young LS.

J Infect Dis. 2003 Jun 15;187(12):1977-80. Epub 2003 Jun 4.

PMID:
12792877
13.

Mycobacterium avium infection of macrophages results in progressive suppression of interleukin-12 production in vitro and in vivo.

Wagner D, Sangari FJ, Kim S, Petrofsky M, Bermudez LE.

J Leukoc Biol. 2002 Jan;71(1):80-8.

PMID:
11781383
14.

The white morphotype of Mycobacterium avium-intracellulare is common in infected humans and virulent in infection models.

Mukherjee S, Petrofsky M, Yaraei K, Bermudez LE, Cangelosi GA.

J Infect Dis. 2001 Dec 1;184(11):1480-4. Epub 2001 Nov 13.

PMID:
11709794
16.

Mycobacterium avium invades the intestinal mucosa primarily by interacting with enterocytes.

Sangari FJ, Goodman J, Petrofsky M, Kolonoski P, Bermudez LE.

Infect Immun. 2001 Mar;69(3):1515-20.

17.

Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.

Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Aralar P, Wu M, Young LS.

Antimicrob Agents Chemother. 2001 Jan;45(1):217-22.

18.

Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice.

Bermudez LE, Nash K, Petrofsky M, Young LS, Inderlied CB.

Antimicrob Agents Chemother. 2000 Oct;44(10):2619-22.

19.
20.
24.

Mycobacterium avium infection of gut mucosa in mice associated with late inflammatory response and intestinal cell necrosis.

Kim SY, Goodman JR, Petrofsky M, Bermudez LE.

J Med Microbiol. 1998 Aug;47(8):725-31.

PMID:
9877194
26.
27.

Reinfusion of discard blood from venous access devices.

Cosca PA, Smith S, Chatfield S, Meleason A, Muir CA, Nerantzis S, Petrofsky M, Williams S.

Oncol Nurs Forum. 1998 Jul;25(6):1073-6.

PMID:
9679265
28.

Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy.

Bermudez LE, Petrofsky M, Kolonoski P, Young LS.

Antimicrob Agents Chemother. 1998 Jan;42(1):180-3.

30.
31.
32.

Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model.

Bermudez LE, Nash KA, Petrofsky M, Young LS, Inderlied CB.

J Infect Dis. 1996 Dec;174(6):1218-22.

PMID:
8940212
34.

Efficacy of azithromycin and rifabutin in preventing infection by Mycobacterium avium complex in beige mice.

Bermudez LE, Petrofsky M, Inderlied CB, Young LS.

J Antimicrob Chemother. 1995 Oct;36(4):641-6.

PMID:
8591938
35.

Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice.

Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Young LS.

Antimicrob Agents Chemother. 1994 Dec;38(12):2717-21.

36.
37.

Exposure to ethanol up-regulates the expression of Mycobacterium avium complex proteins associated with bacterial virulence.

Bermudez LE, Young LS, Martinelli J, Petrofsky M.

J Infect Dis. 1993 Oct;168(4):961-8.

PMID:
8376842
38.
39.

An animal model of Mycobacterium avium complex disseminated infection after colonization of the intestinal tract.

Bermudez LE, Petrofsky M, Kolonoski P, Young LS.

J Infect Dis. 1992 Jan;165(1):75-9.

PMID:
1727899

Supplemental Content

Loading ...
Support Center